Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?

Autor Tunariu, N, Kaye, S B, deSouza, N M
Vydáno 2012

Evaluation of lactate detection using selective multiple quantum coherence in phantoms and brain tumours

Autor Harris, L M, Tunariu, N, Messiou, C, Hughes, J, Wallace, T, DeSouza, N M, Leach, M O, Payne, G S
Vydáno v NMR Biomed (2015)

Use of the temporal median and trimmed mean mitigates effects of respiratory motion in multiple-acquisition abdominal diffusion imaging

Autor Jerome, N P, Orton, M R, d’Arcy, J A, Feiweier, T, Tunariu, N, Koh, D-M, Leach, M O, Collins, D J
Vydáno v Phys Med Biol (2015)

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer

Autor Pezaro, C, Mukherji, D, Tunariu, N, Cassidy, A M, Omlin, A, Bianchini, D, Seed, G, Reid, A H M, Olmos, D, de Bono, J S, Attard, G
Vydáno 2013

Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone

Autor Lorente, D, Omlin, A, Ferraldeschi, R, Pezaro, C, Perez, R, Mateo, J, Altavilla, A, Zafeirou, Z, Tunariu, N, Parker, C, Dearnaley, D, Gillessen, S, de Bono, J, Attard, G
Vydáno v Br J Cancer (2014)

Visceral disease in castration-resistant prostate cancer

Autor Pezaro, C., Omlin, A., Lorente, D., Rodrigues, D. Nava, Ferraldeschi, R., Bianchini, D., Mukherji, D., Riisnaes, R., Altavilla, A., Crespo, M., Tunariu, N., de Bono, J., Attard, G.
Vydáno v Eur Urol (2013)

CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair

Autor Shenoy, T. R., Boysen, G., Wang, M. Y., Xu, Q. Z., Guo, W., Koh, F. M., Wang, C., Zhang, L. Z., Wang, Y., Gil, V., Aziz, S., Christova, R., Rodrigues, D. N., Crespo, M., Rescigno, P., Tunariu, N., Riisnaes, R., Zafeiriou, Z., Flohr, P., Yuan, W., Knight, E., Swain, A., Ramalho-Santos, M., Xu, D. Y., de Bono, J., Wu, H.
Vydáno v Ann Oncol (2017)

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer

Autor Kolinsky, M.P., Rescigno, P., Bianchini, D., Zafeiriou, Z., Mehra, N., Mateo, J., Michalarea, V., Riisnaes, R., Crespo, M., Figueiredo, I., Miranda, S., Nava Rodrigues, D., Flohr, P., Tunariu, N., Banerji, U., Ruddle, R., Sharp, A., Welti, J., Lambros, M., Carreira, S., Raynaud, F.I., Swales, K.E., Plymate, S., Luo, J., Tovey, H., Porta, N., Slade, R., Leonard, L., Hall, E., de Bono, J.S.
Vydáno v Ann Oncol (2020)

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

Autor Basu, B, Krebs, M G, Sundar, R, Wilson, R H, Spicer, J, Jones, R, Brada, M, Talbot, D C, Steele, N, Ingles Garces, A H, Brugger, W, Harrington, E A, Evans, J, Hall, E, Tovey, H, de Oliveira, F M, Carreira, S, Swales, K, Ruddle, R, Raynaud, F I, Purchase, B, Dawes, J C, Parmar, M, Turner, A J, Tunariu, N, Banerjee, S, de Bono, J S, Banerji, U
Vydáno v Ann Oncol (2018)

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Autor Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., Boysen, G., Porta, N., Flohr, P., Gillman, A., Figueiredo, I., Paulding, C., Seed, G., Jain, S., Ralph, C., Protheroe, A., Hussain, S., Jones, R., Elliott, T., McGovern, U., Bianchini, D., Goodall, J., Zafeiriou, Z., Williamson, C.T., Ferraldeschi, R., Riisnaes, R., Ebbs, B., Fowler, G., Roda, D., Yuan, W., Wu, Y.-M., Cao, X., Brough, R., Pemberton, H., A’Hern, R., Swain, A., Kunju, L.P., Eeles, R., Attard, G., Lord, C.J., Ashworth, A., Rubin, M.A., Knudsen, K.E., Feng, F.Y., Chinnaiyan, A.M., Hall, E., de Bono, J.S.
Vydáno v N Engl J Med (2015)